Thursday, 5 December 2019

Reuters Health Report: Sage's oral depression therapy fails in late-stage trial; shares plunge

Reuters.com Newsletter

Sage's oral depression therapy fails in late-stage trial; shares plunge

Sage Therapeutics Inc said on Thursday its experimental drug failed to improve condition of patients with severe depression in a late-stage study, setting up the drugmaker to lose about $4 billion in valuation when the market opens.

Measles toll in Congo exceeds 5,000, WHO says

A measles epidemic in the Democratic Republic of Congo has killed 5,000 people this year, many of them young children, the World Health Organization (WHO) said on Thursday.

Eli Lilly to put Loxo executives in charge of new cancer research unit

U.S. drugmaker Eli Lilly and Co said on Thursday it will create a new cancer research division that will be run by top executives from Loxo Oncology, a cancer-focused biotech company it acquired earlier this year.

Biogen to make case to skeptics for its controversial Alzheimer's drug

Biogen Inc, looking to win over skeptics and health regulators, later on Thursday will present highly anticipated data on its experimental Alzheimer's drug aducanumab, which the U.S. biotech company had declared a failure earlier this year.

Samoa fights measles door-to-door in battle on anti-vaccination messages

Samoa on Thursday closed all non-essential public and private services for two days to combat a measles epidemic that has killed more than 60 people, mostly babies and children, in a battle complicated by a vocal anti-vaccination movement.

AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a form of ovarian cancer.

Novartis CEO plans 80+ submissions for drug approvals through 2022

Novartis is planning more than 80 major submissions to regulators for drug approvals from 2020-2022 in the United States, Europe, Japan and China, Chief Executive Vas Narasimhan said on Thursday ahead of a meeting with analysts and investors.

Acadia Pharma's psychosis drug proven better than placebo in dementia patients

Acadia Pharmaceuticals Inc said on Wednesday dementia patients taking its drug Nuplazid were nearly three times less prone to a psychotic relapse than those on placebo.

Hospital groups file lawsuit to block Trump's price transparency rule

U.S. hospital groups have challenged the Trump administration's rule that requires them to be more transparent about prices they charge patients for healthcare services, according to a lawsuit filed on Wednesday.

New typhoid fever vaccine protects young children

(Reuters Health) - The first field trial of a new typhoid vaccine that can be used in young children provides protection for 81.6% of recipients, opening the door to better control of a disease that affects 11 million people each year and kills roughly 117,000.

Special Report: Powder Keg - FDA bowed to industry for decades as alarms were sounded over talc

At an invitation-only gathering late last year, U.S. regulators and their guests huddled at a hotel near Washington, D.C., to discuss the best way to detect cancer-causing asbestos in talc powders and cosmetics.

Related Videos

Vogue's Wintour: Cherish clothes then pass them on

Swift takes high road, makes history, at AMAs

Introducing the all-new
Reuters News app

The new Reuters News app is here, redesigned from the ground up to fit your busy life.

Get it now on iOS